Codexis, Inc. (CDXS) News

Codexis, Inc. (CDXS)

Today's Latest Price: $18.01 USD

0.15 (0.84%)

Updated Nov 27 1:00pm

Add CDXS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter CDXS News Items

CDXS News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest CDXS News From Around the Web

Below are the latest news stories about Codexis Inc that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis to Hold Second Quarter 2020 Conference Call on August 6

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. We encourage participants to pre-register for the conference call using the following link: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.Those without intern...

Yahoo | July 30, 2020

Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis

Partnership targets accelerating the commercialization of enzymatic DNA synthesis: Codexis invests cash and protein engineering for equity stake in Molecular Assemblies

GlobeNewswire | June 23, 2020

Hedge Funds Are Selling Codexis, Inc. (CDXS)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 22, 2020

Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders

REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of…

GlobeNewswire | June 16, 2020

Edited Transcript of CDXS.OQ earnings conference call or presentation 7-May-20 8:30pm GMT

Q1 2020 Codexis Inc Earnings Call

Yahoo | June 14, 2020

Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets

Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzymes, announce a Co-Marketing & Enzyme Supply Collaboration Agreement for the production and co-marketing of enzymes for life science applications. The first enzyme is a high-fidelity DNA polymerase, following up on Codexis’ previously announced high performance DNA ligase, which was exclusively licensed to Roche in late 2019. The Codexis-developed DNA polymerase has been engineered to deliver high fidelity and uniformity of coverage, providing an accurate and representative DNA diagnostic result.

Yahoo | June 1, 2020

Codexis to Participate in Two Virtual Investment Conferences

REDWOOD CITY, Calif., May 27, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment.

Yahoo | May 27, 2020

Should Codexis Investors Prepare for Slower Growth?

The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.

Yahoo | May 22, 2020

Codexis to Present at the UBS Virtual Healthcare Conference

REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.

Yahoo | May 11, 2020

H.C. Wainwright Sticks to Their Buy Rating for Codexis

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of $12.23.

Yahoo | May 11, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.801 seconds.